A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).

Eric Michael Lander,Brian D. Lehmann,Payal D. Shah,Elizabeth Claire Dees,Tarah Jean Ballinger,Paula R. Pohlmann,Cesar A. Santa-Maria,Yu Shyr,Ingrid A. Mayer,Ben Ho Park,Jennifer A. Pietenpol,Vandana G. Abramson

A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC).

2020

Eric Michael Lander
Brian D. Lehmann
Payal D. Shah
Elizabeth Claire Dees
Tarah Jean Ballinger
Paula R. Pohlmann
Cesar A. Santa-Maria
Yu Shyr
Ingrid A. Mayer
Ben Ho Park
Jennifer A. Pietenpol
Vandana G. Abramson

TPS1112Background: Patients with metastatic triple negative breast cancer (mTNBC) have limited treatment options. Recent studies with a PD-L1 inhibitor and taxane based chemotherapy have demonstrat...

Keywords:

Atezolizumab
Oncology
anti pd 1
Triple-negative breast cancer
Carboplatin
Pathology
Internal medicine
in patient
Medicine
Taxane
treatment options
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations